1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Carbonic Anhydrase
  4. CA Ⅱ Isoform
  5. CA Ⅱ Inhibitor

CA Ⅱ Inhibitor

CA Ⅱ Inhibitors (53):

Cat. No. Product Name Effect Purity
  • HY-B0553
    Methazolamide
    Inhibitor 99.43%
    Methazolamide (L584601) is a sulfonamide derivative used as a carbonic anhydrase inhibitor with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders.
  • HY-B0124
    Zonisamide
    Inhibitor 99.85%
    Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.
  • HY-B0588
    Brinzolamide
    Inhibitor 99.61%
    Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research.
  • HY-B0109A
    Dorzolamide hydrochloride
    Inhibitor 99.92%
    Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
  • HY-B1471
    Fluorometholone acetate
    Inhibitor 98.54%
    Fluorometholone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. Fluorometholone acetate potently inhibits carbonic anhydrase (CA) with IC50s of 2.18 μM and 17.5 μM for hCA-I and hCA-II, respectively. Fluorometholone acetate has anti-inflammatory effect and has the potential for external ocular inflammation research.
  • HY-161522
    α-Glucosidase-IN-63
    Inhibitor
    α-Glucosidase-IN-63 (Compound 4d) is an inhibitor of α-Glucosidase (IC50=0.44 μM). α-Glucosidase-IN-63 inhibits hCA II with an activity of Ki= 7.0 nM. α-Glucosidase-IN-63 is orally effective..
  • HY-168604
    CA Ⅱ-IN-1
    Inhibitor
    CA Ⅱ-IN-1 (compound 2i) is a CA isozyme inhibitor, with IC50 of 0.44 µM. CA Ⅱ-IN-1 can be used for metabolic studies.
  • HY-B1386
    Halazone
    Inhibitor
    Halazone is an atypical antimicrobial sulfonamide derivative and a carbonic anhydrase II inhibitor with a Kd value of 1.45 µM. Halazone protects sodium channels from inactivation. Halazone is widely used for disinfection of drinking water.
  • HY-101087
    Benzenesulphonamide
    Inhibitor 99.51%
    Benzenesulphonamide (compound 1) is a potent carbonic anhydrase inhibitor. Benzenesulphonamide shows CA II inhibitory activity.
  • HY-142849
    Carbonic anhydrase inhibitor 2
    Inhibitor 98.40%
    Carbonic anhydrase inhibitor 1 (compound 7c) is a carbonic anhydrase II inhibitor. Carbonic anhydrase inhibitor 3 reduces the intraocular pressure in glaucomatous rabbits.
  • HY-149301
    hCAIX-IN-18
    Inhibitor 98.52%
    hCAIX-IN-18 (compound 30) is an inhibitor of carbonic anhydrase (CA), with Kis of 3.5 nM, 9.4 nM, 43.0 nM and 8.2 nM for hCAI, hCAII, hCAIX, hCAXII, respectively. hCAIX-IN-18 can be used for cancer research.
  • HY-138365
    EMAC10101d
    Inhibitor 99.77%
    EMAC10101d is a potent and selective toward hCA II inhibitor, with a Ki of 8.1 nM.
  • HY-151916
    Enpp/Carbonic anhydrase-IN-1
    Inhibitor 99.57%
    Enpp/Carbonic anhydrase-IN-1 (compound 1e) is a potent Enpp and carbonic anhydrase inhibitor with IC50s of 1.36, 1.35, 3.00, 0.88, 1.02 μM for NPP1, NPP2, NPP3, CA-II, CA-IX respectively. Enpp/Carbonic anhydrase-IN-1 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonic anhydrase-IN-1 induces Apoptosis.
  • HY-152140
    hCAII-IN-8
    Inhibitor 99.41%
    hCAII-IN-8, an amide, is a highly selective carbonic anhydrase (CA) inhibitor with an IC50 value of 0.18 μM against hCA II.
  • HY-161322
    hCAXII-IN-9
    Inhibitor
    hCAXII-IN-9 (Compound 3I) is a selective inhibitor of hCAXII with Ki values of 28 nM, 7192.6 nM, 188.6 nM, and >100000 nM for hCAXII, hCAI, hCAII, and hCAIX, respectively. hCAXII-IN-9 can be utilized in antitumor research.
  • HY-151472
    hCAIX/XII-IN-6
    Inhibitor
    hCAIX/XII-IN-6 is an orally active carbonic anhydrase (CA) inhibitor. hCAIX/XII-IN-6 inhibits human CA isoforms hCA I, II, IV, IX, and XII with Ki values of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively. hCAIX/XII-IN-6 can be used for the research of rheumatoid arthritis (RA).
  • HY-152141
    hCAII-IN-9
    Inhibitor
    hCAII-IN-9 is a potent carbonic anhydrase inhibitor with IC50s of 1.18 μM (hCA II), 0.17 μM (hCA IX), and 2.99 μM (hCA XII), respectively. hCAII-IN-9 has no blood-brain barrier permeability.
  • HY-150977
    β-Glucuronidase/hCAII-IN-2
    Inhibitor
    β-Glucuronidase/hCAII-IN-2 (Compound 12e) is a potent β-glucuronidase and hCA II inhibitor with an IC50 of 670.7 μM and 21.77 μM, respectively.
  • HY-150976
    β-Glucuronidase/hCAII-IN-1
    Inhibitor
    β-Glucuronidase/hCAII-IN-2 (Compound 12e) is a potent β-glucuronidase and hCA II inhibitor with an IC50 of 440.1 μM and 4.91 μM, respectively.
  • HY-150570
    Carbonic anhydrase inhibitor 14
    Inhibitor
    Carbonic anhydrase inhibitor 14 (Compound 8b) is a carbonic anhydrase (CA) inhibitor with Ki values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 14 can also inhibit CDK2 with an IC50 of 20.3 μM. Carbonic anhydrase inhibitor 14 shows antitumor activity.